Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.16509 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment.
Am J Ophthalmol Case Rep
March 2025
Ophthalmic Surgeons and Consultants of Ohio, Columbus, OH, USA.
Purpose: To describe a case report of the successful management of necrobiotic xanthogranuloma (NXG), a rare periorbital disease.
Observations: A 61-year-old patient presented with bilateral upper and lower lid lesions which were initially misdiagnosed as xanthelasmas and later confirmed to be NXG. Further investigation also uncovered a diagnosis of multiple myeloma.
Cerebrotendinous xanthomatosis: A complex interplay between a clinically and genetically heterogeneous condition.
Eur J Neurol
January 2025
Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia.
Article Synopsis
- CTX (cerebrotendinous xanthomatosis) is a rare genetic lipid storage disease that can be difficult to diagnose due to its varied symptoms, often leading to confusion with other conditions like hereditary spastic paraplegia (HSP).
- A case study of a 53-year-old woman showed a 25-year history of spastic paraparesis and, after years of undiagnosed progression, she was finally diagnosed with CTX through genetic testing revealing a variant in the CYP27A1 gene.
- The patient's treatment included chenodeoxycholic acid, which stabilized her condition, but the advanced state of her disease limited improvement, highlighting the need for thorough investigation and awareness of CTX
Treatment of Xanthelasma Palpebrarum Using Trichloroacetic Acid 80.
J Clin Aesthet Dermatol
November 2024
All authors are affiliated with the Institute of Cosmetic and Laser Surgery in Oakville, Ontario. Canada.
Objective: We sought to analyze the effectiveness, recurrence, safety, and patient satisfaction rates following xanthelasma palpebrarum (XP) treatment with trichloroacetic acid (TCA) 80%.
Methods: This was a retrospective review of patients treated with TCA 80% for XP between January 2012 and August 2022. A prospective telephone questionnaire was administered to the same patient population to evaluate recurrence, patient satisfaction, and side effects.
Effective treatment of xanthelasma palpebrarum using Er:YAG laser.
Lasers Med Sci
January 2025
Department of Plastic and Reconstructive Surgery, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea.
Xanthelasma palpebrarum (XP), characterized by soft, yellowish plaque primarily on the eyelids, is often associated with lipid metabolism disorders. XP can cause aesthetic concerns that affect social interactions and requires careful treatment evaluations due to potential complications and associations with systemic conditions. We aimed to assess the efficacy of and recurrence rates with erbium:yttrium aluminum garnet (Er:YAG) laser therapy in the treatment of XP.
View Article and Find Full Text PDFCerebrotendinous xanthomatosis: a literature review and case study.
Front Cardiovasc Med
December 2024
Department of Cardiology, INSERM UMR 1295, Toulouse University Hospital, Toulouse, France.
Cerebrotendinous xanthomatosis (CTX) is a rare but treatable inherited neurometabolic disorder that can lead to severe sequelae if left untreated. Chenodeoxycholic acid is a safe and effective treatment for CTX. Early diagnosis is essential to improve patient outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!